Cholestyramine


CAS No. : 11041-12-6

(Synonyms: Cholestyramine resin; Colestyramine)

11041-12-6
Price and Availability of CAS No. : 11041-12-6
Size Price Stock
500mg $50 In-stock
1g $72 In-stock
5g $145 In-stock
10g $205 In-stock
25g $350 In-stock
50g $490 In-stock
100g $686 In-stock
200 g Get quote
500 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-104081
M.Wt: 1000.00
Formula: N/A
Purity: >98 %
Solubility: DMSO : < 1 mg/mL;1M HCl : < 1 mg/mL;H2O : < 0.1 mg/mL
Introduction of 11041-12-6 :

Cholestyramine (Colestyramine) is a bile acid binding resin and can inhibit intestinal bile acid absorption which results in the increasing bile acid synthesis from cholesterol. In Vitro: Cholestyramine (0.1-50 μg/mL) produced the most dramatic results after a 24-hour exposure; an efflux rate of 65% compared with control cells. Cholestyramine is an anion-exchange resin and is insoluble in water. alcohol, chloro-form, and ether. For the assay, cholestyramine is initially wetted with a small amount of DMSO further diluting with media. A blank sample prepared with dimethylsulfoxide DMSO without cholestyramine displayed no differences from the control samples[3]. In Vivo: Cholestyramine (Colestyramine) is a bile acid binding resin and can inhibit intestinal bile acid absorption which results in the increasing bile acid synthesis from cholesterol[1]. Results reveal that GSPE treatment alone, and co-administration with Cholestyramine (Colestyramine), regulate BA, cholesterol and TG metabolism differently compare to Cholestyramine administration alone. Notably, GSPE decreases intestinal apical sodium-dependent bile acid transporter (Asbt) gene expression, while Cholestyramine significantly induces expression. Administration with GSPE or Cholestyramine robustly induces hepatic BA biosynthetic gene expression, especially cholesterol 7α-hydroxylase (Cyp7a1), compare to control, while co-administration further enhances expression. Treatment with Cholestyramine induces both intestinal and hepatic cholesterologenic gene expression, while co-administration with GSPE attenuates the Cholestyramine-inducing increase in the liver but not in the intestine. Cholestyramine also induces hepatic lipogenic gene expression, which is attenuated by co-administration with GSPE[2].

Your information is safe with us.